Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
- The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Overview 6
Therapeutics Development 7
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Stage of Development 7
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Therapy Area 8
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Indication 9
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Companies 12
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Products under Development by Universities/Institutes 14
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development 23
Cytheris SA 23
Genexine Inc 24
GlaxoSmithKline Plc 25
OSE Immunotherapeutics 26
Pfizer Inc 27
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles 28
Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CYT-107 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
EFFI-7H - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
GSK-2618960 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GX-I7 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PF-06342674 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Projects 37
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products 39
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Featured News & Press Releases 40
Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine 40
Jun 12, 2013: GSK Halts Clinical Trials Of Multiple Sclerosis Drug GSK-2618960 After Fraud Claim 40
Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leucoencephalopathy 41
Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation 41
Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy 42
Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients 43
Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Nonresponders To Standard Of Care 44
Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting 46
May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions 47
May 11, 2011: Cytheris, Lyon And ImmunID Announce Initiation Of Phase IIa Combination Trial Of IL-7 And XELODA In Metastatic Breast Cancer Treatment 48
Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107 50
Dec 07, 2010: Cytheris Announces Interim Phase I Study Results Of CYT107 In Treatment Of Post-Transplant Patients 51
Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients 53
Oct 19, 2010: Cytheris Initiates ORVACS-Sponsored Phase II Clinical Study To Attack Viral Reservoir Of HIV Patients 54
Sep 23, 2010: Cytheris Initiates Phase II Clinical Trial Of CYT107 In Chronically Infected HIV Patients 55

Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Cytheris SA, H2 2016 23
Pipeline by Genexine Inc, H2 2016 24
Pipeline by GlaxoSmithKline Plc, H2 2016 25
Pipeline by OSE Immunotherapeutics, H2 2016 26
Pipeline by Pfizer Inc, H2 2016 27
Dormant Projects, H2 2016 37
Dormant Projects (Contd..1), H2 2016 38
Discontinued Products, H2 2016 39